Source: Virtual Congress 2021 – Exercise tolerance, supportive care and more in non-pulmonary fibrosis interstitial lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
K. Domvri (Thessaloniki, Greece), A. Apostolopoulos (Thessaloniki, Greece), I. Organtzis (Thessaloniki, Greece), E. Fouka (Thessaloniki, Greece), L. Bina (Thessaloniki, Greece), T. Kontakiotis (Thessaloniki, Greece), D. Papakosta (Thessaloniki, Greece). Late Breaking Abstract - Prognostic value of serum biomarkers in patients with idiopathic pulmonary fibrosis and correlation with disease progression.. 2348

Member's Comments

No comment yet.

Related content which might interest you: MMP-7 is a predictive biomarker of disease progression in patients with idiopathic pulmonary fibrosis Source: ERJ Open Res, 3 (1) 00074-2016; 10.1183/23120541.00074-2016 Year: 2017 Late Breaking Abstract - Systemic ferritin is an early disease biomarker for silicosis patients Source: Virtual Congress 2021 – Prognostic markers of disease progression in non-idiopathic pulmonary fibrosis interstitial lung diseases Year: 2021 Late Breaking Abstract - Elevated growth differentiation factor 15 in serum correlated with acute exacerbation of idiopathic pulmonary fibrosis Source: International Congress 2019 – Idiopathic pulmonary fibrosis and surroundings Year: 2019 Serum exosomes from IPF patients display a fibrotic miRNA profile that correlates to clinical measures of disease severity Source: International Congress 2015 – Interstitial lung diseases II Year: 2015 Late Breaking Abstract - Correlation of CT severity score and Inflammatory markers to predict the disease severity in COVID 19 patients Source: Virtual Congress 2021 – COVID – 19: treatments and predictive factors Year: 2021 Late Breaking Abstract - Survival and course of lung function in patients with idiopathic pulmonary fibrosis with or without antifibrotic treatment: long-term results of the INSIGHTS-IPF registry Source: International Congress 2019 – Idiopathic pulmonary fibrosis and surroundings Year: 2019 Prognostic evaluation in Chinese patients with idiopathic pulmonary fibrosis Source: Annual Congress 2008 - Management of idiopathic pulmonary fibrosis: what can we learn from the pathophysiology? Year: 2008 Correlation between physical activity and prognostic markers in patients with idiopathic pulmonary fibrosis Source: Virtual Congress 2020 – Prognosis and biomarkers of idiopathic pulmonary fibrosis Year: 2020 Serum KL-6 as a multidimensional biomarker in patients with idiopathic pulmonary fibrosis Source: International Congress 2016 – IPF: from pathogenesis to treatment II Year: 2016 Clinical significance of autoantibody screening in patients with idiopathic pulmonary fibrosis Source: Annual Congress 2013 –Diffuse pulmonary fibrosis Year: 2013 Discovery and validation of peripheral blood gene expression profiles predictive of poor outcome and disease progression in idiopathic pulmonary fibrosis Source: International Congress 2014 – Pathogenetic mechanisms in pulmonary fibrosis Year: 2014 Prognostic evaluation in idiopathic pulmonary fibrosis (IPF) Source: Annual Congress 2011 - What is new in the approach to pulmonary fibrosis? Year: 2011 Late Breaking Abstract - Association of lung clearance index with survival in patients with cystic fibrosis Source: International Congress 2019 – Advances in care and monitoring of cystic fibrosis Year: 2019 Clinical course of idiopathic pulmonary fibrosis (IPF): Prediction and outcome Source: Annual Congress 2011 - What is new in the approach to pulmonary fibrosis? Year: 2011 Prognostic value of circulating KL-6 in idiopathic pulmonary fibrosis Source: Annual Congress 2004 - Fibrosing lung diseases Year: 2004 Late Breaking Abstract - Increased serum levels of YKL-40 in male smoking chronic obstructive pulmonary disease patients associated with altered miRNA levels in alveolar macrophages Source: Virtual Congress 2020 – New biomarkers for management of obstructive diseases Year: 2020 Correlation of a progression of fibrotic changes in idiopathic pulmonary fibrosis 1 year after a diagnosis with initial functional and immunologic parameters Source: Eur Respir J 2004; 24: Suppl. 48, 667s Year: 2004 IL8 as a marker of severity of disease progression in patients with idiopathic pulmonary fibrosis (IPF) Source: Eur Respir J 2007; 30: Suppl. 51, 373s Year: 2007 Incidence and predictive factors of lung cancer in patients with idiopathic pulmonary fibrosis Source: ERJ Open Res, 4 (1) 00111-2016; 10.1183/23120541.00111-2016 Year: 2018 Functional and prognostic significance of relationship between VC and TLC in patients with idiopathic pulmonary fibrosis (IPF) Source: Eur Respir J 2005; 26: Suppl. 49, 334s Year: 2005